Barinthus Biotherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell BRNS and other ETFs, options, and stocks.About BRNS
Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs.
CEOWilliam Enright
CEOWilliam Enright
Employees105
Employees105
HeadquartersDidcot, Oxfordshire
HeadquartersDidcot, Oxfordshire
Founded2021
Founded2021
Employees105
Employees105
BRNS Key Statistics
Market cap28.53M
Market cap28.53M
Price-Earnings ratio-0.37
Price-Earnings ratio-0.37
Dividend yield—
Dividend yield—
Average volume43.37K
Average volume43.37K
High today$0.75
High today$0.75
Low today$0.692
Low today$0.692
Open price$0.7213
Open price$0.7213
Volume84.83K
Volume84.83K
52 Week high$2.92
52 Week high$2.92
52 Week low$0.64
52 Week low$0.64
Stock Snapshot
As of today, Barinthus Biotherapeutics(BRNS) shares are valued at $0.69. The company's market cap stands at 28.53M, with a P/E ratio of -0.37.
On 2025-12-09, Barinthus Biotherapeutics(BRNS) stock moved within a range of $0.69 to $0.75. With shares now at $0.69, the stock is trading 0.0% above its intraday low and -7.7% below the session's peak.
Trading volume for Barinthus Biotherapeutics(BRNS) stock has reached 84.83K, versus its average volume of 43.37K.
The stock's 52-week range extends from a low of $0.64 to a high of $2.92.
The stock's 52-week range extends from a low of $0.64 to a high of $2.92.